P-22 Efficacy of sorafenib in treatment of advanced hepatocellular carcinoma in the Mexican population: Evidence from a third level hospital in Mexico

Abstract

The determination of serum biomarkers was carried out by Milliplex Map Human Circulation Biomarker Kit. PD-L1 was determined using the Human ProcartaPlexÔ Kit; oncomarker CA 72-4 was identified using ELISA. Concentrations are indicated in pg/ ml. Statistic processing included Kruskal-Wallis and Mann-Whitney analysis. Informed consent was obtained for the examination of patients.Results: A group of patients with first-time diagnosis of colorectal cancer (n¼215) took part in the investigation. The average age: (Nf [25%;75%]) 66.6 years old [62;72] 45% men and 55% women. Biomarker blood test was done prior to surgery. The control group included 53 healthy participants aged 47 [43;57]. The comparison group included 55 patients aged 59,5 [53,3;65] with inflammatory intestinal diseases. The patients were divided into subgroups: with the presence of invasive growth (n¼69) and with its absence (n¼153). In none of the cases did the biomarkers studied reveal significant differences in the content between the group of healthy individuals and those with non-cancerous bowel diseases. Classical markers CA 19-9 (12,0 [5,46;18,70], p< 0,0001) rose equally in both groups in CRC, with no difference between the groups. Markers such as CYFRA21-1 (1416,14 [906,1; 2213,68], p< 0,001) and OPN (6121 [3970; 11536], p¼0,001) in the group with invasive growth of CRC significantly differed both from the control group and from the comparison group, however, they did not differ between the groups with invasive and non-invasive tumor growth. An increase in the serum level of the PDL-1 in the group with invasive CRC reached significance with the control group (but not the comparison group), but it also almost did not differ within the group with CRC. VEGF (115,33 [90,6; 156,0], p¼0,0016) behaves atypically in our study, as it grew significantly in the group with non-invasive growth compared with the group with invasive growth; it was almost identical to non-oncological groups. The serum level of sFASL (57,63 [44,17; 86,86], p¼0,0001) but not sFAS,) behaved similarly, reaching a maximum in the group with non-invasive tumor growth. Conclusion:We found a relationship between the presence of invasion and the rates of biomarkers (sFASL) in the Kazakh population.